Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34828
Title: Cardiometabolic Effects of Denosumab in Premenopausal Women with Breast Cancer Receiving Estradiol Suppression: RCT.
Austin Authors: Ramchand, Sabashini K ;Hoermann, Rudolf;White, Shane ;Yeo, Belinda ;Francis, Prudence A;Xu, Cecilia L H;Zajac, Jeffrey D ;Seeman, Ego ;Grossmann, Mathis 
Affiliation: Medicine (University of Melbourne)
Department of Medicine, Austin Health, University of Melbourne, Victoria, Australia.
Olivia Newton-John Cancer Wellness and Research Centre
Department of Medicine, Austin Health, University of Melbourne, Victoria, Australia.;Olivia Newton-John Cancer & Wellness Centre, Austin Health, Victoria, Australia.
Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
Department of Medicine, Austin Health, University of Melbourne, Victoria, Australia.
Department of Medicine, Austin Health, University of Melbourne, Victoria, Australia.;Department of Endocrinology, Austin Health, Victoria, Australia.
Department of Medicine, Austin Health, University of Melbourne, Victoria, Australia.;Department of Endocrinology, Austin Health, Victoria, Australia.
Department of Medicine, Austin Health, University of Melbourne, Victoria, Australia.;Department of Endocrinology, Austin Health, Victoria, Australia.
Issue Date: 5-Jan-2024
Date: 2024
Publication information: The Journal of Clinical Endocrinology and Metabolism 2024-01-05
Abstract: Menopause is associated with changes in musculoskeletal, body composition, and metabolic parameters that may be amplified in premenopausal women receiving estradiol suppression for breast cancer. Denosumab offsets deleterious skeletal effects of estradiol suppression and has been reported to have effects on body composition and metabolic parameters in pre-clinical and observational studies, though evidence from double-blind randomized controlled trials is limited. To assess the effect of denosumab on body composition and metabolic parameters. In a pre-specified secondary analysis of a 12-month randomized, double-blind, placebo-controlled trial, 68 premenopausal women with breast cancer initiating ovarian function suppression and aromatase inhibition were randomized to denosumab 60-mg or placebo administered at baseline and 6 months. Outcome measures were total and regional fat and lean mass (DXA), body mass index (BMI), waist and hip circumference, fasting glucose, HOMA-IR, and lipid profile. Using a mixed model, between-group mean adjusted differences, MAD, [95% confidence interval], over time are reported. Over 12 months, relative to placebo, android and gynoid fat mass decreased in the denosumab group (-266 g [95%CI -453 to -79], P = 0.02, and -452 g [95%CI -783 to -122], P = 0.03, respectively). Total fat mass and waist circumference were lower in the denosumab group but not significantly so (-1792g [95% CI -3346 to -240], P = 0.08 and (- 3.77 cm [95% CI -6.76 to -0.79], P = 0.06, respectively). No significant treatment effects were detected in lean mass, BMI, hip circumference, fasting glucose, HOMA-IR, or lipid profile. In premenopausal women receiving estradiol suppression, denosumab decreases some measures of fat mass with no detectable effects on other measures of body composition or metabolic parameters.
URI: https://ahro.austin.org.au/austinjspui/handle/1/34828
DOI: 10.1210/clinem/dgae003
ORCID: 0000-0002-6755-8469
0000-0001-8261-3457
Journal: The Journal of Clinical Endocrinology and Metabolism
PubMed URL: 38181438
ISSN: 1945-7197
Type: Journal Article
Subjects: body composition
breast cancer
denosumab
estradiol suppression
glucose metabolism
lipids
Appears in Collections:Journal articles

Show full item record

Page view(s)

30
checked on Jul 16, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.